Thermalin is engineering new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
Founded in 2010 based on pioneering work by Dr. Michael Weiss on the structure and function of insulin analogues, Thermalin is overcoming the limitations of existing insulin products by re-engineering the insulin molecule to be more stable and to act more selectively. Thermalin’s formulations of these new molecules enable new delivery devices and systems that will transform lives. On September 28, Thermalin announced a worldwide collaboration with Sanofi on two of its insulin programs as well as a $17.5M Series A Financing that is being led by Sanofi.
No open positions at this time